LORLATINIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01ED05
UNII: OSP71S83EU

Structure
InChI Key IIXWYSCJSQVBQM-LLVKDONJSA-N
Smile C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21
InChI
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H19FN6O2
Molecular Weight 406.42
AlogP 2.8
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 0.0
Polar Surface Area 110.06
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR ALK tyrosine kinase receptor inhibitor FDA
Primary Target
ALK receptor tyrosine kinase
c-ros oncogene 1, receptor tyrosine kinase
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TKL protein kinase group TKL protein kinase STKR family TKL protein kinase STKR Type 1 subfamily
- 0-77 - 1-8 -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Ack family
- 17 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Alk family
- 3 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Fak family
- 14 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Fer family
- 3 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Sev family
- 0 - 0-12 -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Src family
- 53 - - -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Trk family
- 24 - 23-23 -
Surface antigen
- 0 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC34 family of sodium phosphate co-transporters
- 0 - - -
Unclassified protein
- 0-77 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Lymphoma, Large-Cell, Anaplastic 2 D017728 ClinicalTrials
Neuroblastoma 1 D009447 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.4
Nervous system disorders
12.4
Respiratory, thoracic and mediastinal disorders
10.15
Psychiatric disorders
9.64
Metabolism and nutrition disorders
9.14
Cardiac disorders
7.03
Investigations
6.02
Vascular disorders
5.0
Musculoskeletal and connective tissue disorders
4.42
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.13
Gastrointestinal disorders
3.19
Infections and infestations
3.12
Injury, poisoning and procedural complications
3.05
Renal and urinary disorders
2.47
Blood and lymphatic system disorders
2.1

Cross References

Resources Reference
CAS NUMBER 1454846-35-5
ChEBI 143117
ChEMBL CHEMBL3286830
DrugBank DB12130
DrugCentral 5302
FDA SRS OSP71S83EU
Guide to Pharmacology 7476
PDB 5P8
PubChem 71731823
SureChEMBL SCHEMBL15261807
ZINC ZINC000098208524
CONTENTS